The Chart looks to me to have over ran, too far up. Dont ask me about the Business Model or the revenue because I dont know. But to me the Chart looks like it needs a realy good pull back, to $8-
PTX This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution